<PAPER>
  <mode2 name="plos_1_1_arathi" hasDoc="yes" version="1258"/>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="2.0" xml:lang="EN">
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
        <journal-id journal-id-type="publisher-id">plos</journal-id>
        <journal-id journal-id-type="pmc">plosone</journal-id>
        <journal-title>PLoS ONE</journal-title>
        <issn pub-type="epub">1932-6203</issn>
        <publisher>
          <publisher-name>Public Library of Science</publisher-name>
          <publisher-loc>San Francisco, USA</publisher-loc>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="publisher-id">09-PONE-RA-08666R1</article-id>
        <article-id pub-id-type="doi">10.1371/journal.pone.0005804</article-id>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Research Article</subject>
          </subj-group>
          <subj-group subj-group-type="Discipline">
            <subject>Biochemistry/Chemical Biology of the Cell</subject>
            <subject>Biochemistry/Drug Discovery</subject>
            <subject>Cell Biology/Cellular Death and Stress Responses</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>
            <s sid="1">Sulindac Enhances the Killing of Cancer Cells Exposed to Oxidative Stress<CoreSc1 atype="GSC" type="Res" conceptID="Res1" novelty="None" advantage="None"/></s>
          </article-title>
          <alt-title alt-title-type="running-head">Sulindac, Cancer and ROS</alt-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author" xlink:type="simple">
            <name name-style="western">
              <surname>Marchetti</surname>
              <given-names>Maria</given-names>
            </name>
            <xref ref-type="aff" rid="aff2">
              <sup>2</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author" xlink:type="simple">
            <name name-style="western">
              <surname>Resnick</surname>
              <given-names>Lionel</given-names>
            </name>
            <xref ref-type="aff" rid="aff2">
              <sup>2</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author" xlink:type="simple">
            <name name-style="western">
              <surname>Gamliel</surname>
              <given-names>Edna</given-names>
            </name>
            <xref ref-type="aff" rid="aff1">
              <sup>1</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author" xlink:type="simple">
            <name name-style="western">
              <surname>Kesaraju</surname>
              <given-names>Shailaja</given-names>
            </name>
            <xref ref-type="aff" rid="aff2">
              <sup>2</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author" xlink:type="simple">
            <name name-style="western">
              <surname>Weissbach</surname>
              <given-names>Herbert</given-names>
            </name>
            <xref ref-type="aff" rid="aff2">
              <sup>2</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author" xlink:type="simple">
            <name name-style="western">
              <surname>Binninger</surname>
              <given-names>David</given-names>
            </name>
            <xref ref-type="aff" rid="aff1">
              <sup>1</sup>
            </xref>
            <xref ref-type="aff" rid="aff2">
              <sup>2</sup>
            </xref>
            <xref ref-type="corresp" rid="cor1">
              <sup>*</sup>
            </xref>
          </contrib>
        </contrib-group>
        <aff id="aff1">
          <label>1</label>
          <addr-line>Department of Biological Sciences, Florida Atlantic University, Boca Raton, Florida, United States of America</addr-line>
        </aff>
        <aff id="aff2">
          <label>2</label>
          <addr-line>Center for Molecular Biology and Biotechnology, Florida Atlantic University, Boca Raton, Florida, United States of America</addr-line>
        </aff>
        <contrib-group>
          <contrib contrib-type="editor" xlink:type="simple">
            <name name-style="western">
              <surname>Bauer</surname>
              <given-names>Joseph Alan</given-names>
            </name>
            <role>Editor</role>
            <xref ref-type="aff" rid="edit1"/>
          </contrib>
        </contrib-group>
        <aff id="edit1">Bauer Research Foundation, United States of America</aff>
        <author-notes>
          <corresp id="cor1">* E-mail: <email xlink:type="simple">binninge@fau.edu</email></corresp>
          <fn fn-type="con">
            <p>Conceived and designed the experiments: MM HW DB. Performed the experiments: MM EG SK. Analyzed the data: MM LR EG SK HW DB. Wrote the paper: MM HW DB.</p>
          </fn>
        </author-notes>
        <pub-date pub-type="collection">
          <year>2009</year>
        </pub-date>
        <pub-date pub-type="epub">
          <day>5</day>
          <month>6</month>
          <year>2009</year>
        </pub-date>
        <volume>4</volume>
        <issue>6</issue>
        <elocation-id>e5804</elocation-id>
        <history>
          <date date-type="received">
            <day>10</day>
            <month>2</month>
            <year>2009</year>
          </date>
          <date date-type="accepted">
            <day>11</day>
            <month>5</month>
            <year>2009</year>
          </date>
        </history>
        <copyright-statement>Marchetti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement>
        <copyright-year>2009</copyright-year>
        <abstract>
          <sec>
            <title>Background</title>
            <p>
              <s sid="2">Sulindac is an FDA-approved non-steroidal anti-inflammatory drug (NSAID) that affects prostaglandin production by inhibiting cyclooxygenases (COX) 1 and 2.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj1" novelty="None" advantage="None"/></s>
              <s sid="3">Sulindac has also been of interest for more than decade as a chemopreventive for adenomatous colorectal polyps and colon cancer.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac1" novelty="None" advantage="None"/></s>
            </p>
          </sec>
          <sec>
            <title>Principal Findings</title>
            <p>
              <s sid="4">Pretreatment of human colon and lung cancer cells with sulindac enhances killing by an oxidizing agent such as tert-butyl hydroperoxide (TBHP) or hydrogen peroxide.<CoreSc1 atype="GSC" type="Res" conceptID="Res2" novelty="None" advantage="None"/></s>
              <s sid="5">This effect does not involve cyclooxygenase (COX) inhibition.<CoreSc1 atype="GSC" type="Res" conceptID="Res3" novelty="None" advantage="None"/></s>
              <s sid="6">However, under the conditions used, there is a significant increase in reactive oxygen species (ROS) within the cancer cells and a loss of mitochondrial membrane potential, suggesting that cell death is due to apoptosis, which was confirmed by Tunel assay.<CoreSc1 atype="GSC" type="Res" conceptID="Res4" novelty="None" advantage="None"/></s>
              <s sid="7">In contrast, this enhanced killing was not observed with normal lung or colon cells.<CoreSc1 atype="GSC" type="Res" conceptID="Res5" novelty="None" advantage="None"/></s>
            </p>
          </sec>
          <sec>
            <title>Significance</title>
            <p>
              <s sid="8">These results indicate that normal and cancer cells handle oxidative stress in different ways and sulindac can enhance this difference.<CoreSc1 atype="GSC" type="Con" conceptID="Con1" novelty="None" advantage="None"/></s>
              <s sid="9">The combination of sulindac and an oxidizing agent could have therapeutic value.<CoreSc1 atype="GSC" type="Con" conceptID="Con2" novelty="None" advantage="None"/></s>
            </p>
          </sec>
        </abstract>
        <counts>
          <page-count count="9"/>
        </counts>
      </article-meta>
    </front>
    <body>
      <sec id="s1">
        <title>Introduction</title>
        <p>
          <s sid="10">Sulindac was one of the early non-steroidal anti-inflammatory drugs (NSAIDs), which affect prostaglandin production by inhibiting cyclooxygenases (COX) 1 and 2 <xref ref-type="bibr" rid="pone.0005804-Vane1">[1]</xref>.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj2" novelty="None" advantage="None"/></s>
          <s sid="11">For more than a decade, sulindac has also been of interest as a chemopreventive treatment for adenomatous colorectal polyps and colon cancer <xref ref-type="bibr" rid="pone.0005804-Boolbol1">[2]</xref>&#8211;<xref ref-type="bibr" rid="pone.0005804-Taketo2">[5]</xref>, especially in patients with familial adenomatous polyposis <xref ref-type="bibr" rid="pone.0005804-Guldenschuh1">[6]</xref>.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac2" novelty="None" advantage="None"/></s>
          <s sid="12">Sulindac has also been reported as a chemopreventive agent for mouse urinary bladder cancer <xref ref-type="bibr" rid="pone.0005804-Rao1">[7]</xref>.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac3" novelty="None" advantage="None"/></s>
          <s sid="13">The anti-tumorigenic activity of sulindac against colon cancer may involve both COX inhibition <xref ref-type="bibr" rid="pone.0005804-Boolbol1">[2]</xref> and activities that are independent of COX inhibition <xref ref-type="bibr" rid="pone.0005804-Grosch1">[8]</xref>&#8211;<xref ref-type="bibr" rid="pone.0005804-Yamazaki1">[11]</xref>.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac4" novelty="None" advantage="None"/></s>
          <s sid="14">It has been reported that sulindac induces apoptosis of colon cancer cells, <xref ref-type="bibr" rid="pone.0005804-Yamazaki1">[11]</xref>, <xref ref-type="bibr" rid="pone.0005804-Richter1">[12]</xref>, which appears to involve changes in gene expression <xref ref-type="bibr" rid="pone.0005804-Richter1">[12]</xref>&#8211;<xref ref-type="bibr" rid="pone.0005804-Wick1">[18]</xref>.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac5" novelty="None" advantage="None"/></s>
        </p>
        <p>
          <s sid="15">Sulindac is a pro-drug that must be converted to the active COX-inhibitor, sulindac sulfide <xref ref-type="bibr" rid="pone.0005804-Duggan1">[19]</xref>.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj3" novelty="None" advantage="None"/></s>
          <s sid="16">We have previously shown that conversion of sulindac to sulindac sulfide can be catalyzed by MsrA, a member of the methionine sulfoxide reductase (Msr) family of enzymes <xref ref-type="bibr" rid="pone.0005804-Etienne1">[20]</xref>.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac6" novelty="None" advantage="None"/></s>
          <s sid="17">The Msr system has been studied in detail in recent years, after it was shown that MsrA may play a role in aging and age related diseases <xref ref-type="bibr" rid="pone.0005804-Moskovitz1">[21]</xref>&#8211;<xref ref-type="bibr" rid="pone.0005804-Weissbach1">[23]</xref>.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac7" novelty="None" advantage="None"/></s>
          <s sid="18">The obvious function of the Msr system is to reduce methionine sulfoxide (Met(o)) in proteins back to methionine (Met) (reviewed in <xref ref-type="bibr" rid="pone.0005804-Weissbach1">[23]</xref>), although it also functions as part of a ROS scavenger system, in which the Msr system permits Met residues in protein to function as catalytic antioxidants <xref ref-type="bibr" rid="pone.0005804-Levine1">[24]</xref>.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac8" novelty="None" advantage="None"/></s>
          <s sid="19">Support for the scavenger role of MsrA has come from recent studies with both PC-12 neuronal cells, in which MsrA was overexpressed <xref ref-type="bibr" rid="pone.0005804-Yermolaieva1">[25]</xref>, and human lens cells, in which MsrA expression was down regulated <xref ref-type="bibr" rid="pone.0005804-Marchetti1">[26]</xref>.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac9" novelty="None" advantage="None"/></s>
          <s sid="20">Thus, there is considerable evidence to suggest that the Msr system plays an important role in protecting cells against oxidative damage.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac10" novelty="None" advantage="None"/></s>
        </p>
        <p>
          <s sid="21">Since sulindac is a substrate for MsrA <xref ref-type="bibr" rid="pone.0005804-Etienne1">[20]</xref>, it seemed reasonable that the killing of cancer cells by sulindac might involve oxidative stress.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp1" novelty="None" advantage="None"/></s>
          <s sid="22">Additionally, we wanted to determine whether normal cells and cancer cells responded in a similar way(s) after sulindac treatment and oxidative stress.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa1" novelty="None" advantage="None"/></s>
          <s sid="23">In a preliminary study, we showed that treatment of a squamous cell cancer cell line with sulindac and an oxidizing agent led to nearly a 500% increase in intracellular ROS levels and significant cell death.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac11" novelty="None" advantage="None"/></s>
          <s sid="24">In contrast, normal human epidermal keratinocytes did not show an increase in ROS levels or cell death.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac12" novelty="None" advantage="None"/></s>
          <s sid="25">These results led to a limited clinical trial that showed promising potential of using topical application of sulindac and hydrogen peroxide for treatment of actinic keratoses <xref ref-type="bibr" rid="pone.0005804-Resnick1">[27]</xref>.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot1" novelty="None" advantage="None"/></s>
        </p>
        <p>
          <s sid="26">In the present studies we extended these earlier results using cancer cell lines derived from lung and colon tissue.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj4" novelty="None" advantage="None"/></s>
          <s sid="27">We provide further evidence that the enhanced killing observed with sulindac and oxidative stress involves mitochondrial dysfunction leading to cell death via apoptosis.<CoreSc1 atype="GSC" type="Con" conceptID="Con3" novelty="None" advantage="None"/></s>
          <s sid="28">These new data strengthen the potential for specifically enhancing the therapeutic application of sulindac and its derivatives for cancer treatment by using them in conjunction with a compound that produces reactive oxygen species (ROS).<CoreSc1 atype="GSC" type="Con" conceptID="Con4" novelty="None" advantage="None"/></s>
        </p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <sec id="s2a">
          <title>Sulindac enhances the killing of tumor cells by oxidative stress, but does not involve either COX inhibition or the Msr system</title>
          <p>
            <s sid="29">Human lung and colon cancer cell lines were preincubated in the presence or absence of sulindac for 48 hours.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/></s>
            <s sid="30">Excess sulindac was removed by washing prior to the 2 hr incubation with TBHP as described in the <xref ref-type="sec" rid="s4">Materials and Methods</xref>.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/></s>
            <s sid="31">Sulindac was used at 500 &#181;M final concentration since preliminary experiments using sulindac at this concentration showed no significant effect on cell viability for either of the cancer cell lines.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp3" novelty="None" advantage="None"/></s>
          </p>
          <p>
            <s sid="32">Each cancer cell line had a marked decrease in cell viability in the presence of TBHP following pretreatment with 500 &#181;M sulindac (<xref ref-type="fig" rid="pone-0005804-g001">Figure 1A and 1B</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs1" novelty="None" advantage="None"/></s>
            <s sid="33">Viability of lung cancer cells pretreated with sulindac was reduced by greater than 80% following incubation for 2 hr with 240 &#181;M TBHP when compared to control cells that were not pretreated with sulindac (<xref ref-type="fig" rid="pone-0005804-g001">Figure 1A</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res6" novelty="None" advantage="None"/></s>
            <s sid="34">Similar responses to TBHP were observed with sulindac treated colon cancer cells (<xref ref-type="fig" rid="pone-0005804-g001">Figure 1B</xref>), although a higher concentration of TBHP was required for significant killing of the colon cancer cells.<CoreSc1 atype="GSC" type="Res" conceptID="Res7" novelty="None" advantage="None"/></s>
            <s sid="35">Sulindac also enhanced the killing of both cancer cell lines when TBHP was replaced with hydrogen peroxide, at concentrations between 1.0 mM and 6.0 mM (<xref ref-type="fig" rid="pone-0005804-g002">Figure 2</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs2" novelty="None" advantage="None"/></s>
          </p>
          <fig id="pone-0005804-g001" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pone.0005804.g001</object-id>
            <label>Figure 1</label>
            <caption>
              <title>Effect of sulindac on the viability of cancer cells in response to oxidative stress.</title>
              <p>Lung cancer cells (A) or colon cancer cells (B) were incubated in the presence (&#9642;) or absence (&#9633;) of 500 &#181;M sulindac for 48 hr. Cells were then washed to remove the free sulindac prior to incubation for 2 hr with the indicated concentration of TBHP and cell viability was measured using the MTS assay described in <xref ref-type="sec" rid="s4">Materials &amp; Methods</xref>. Cell viability is expressed as % of control (cells not pretreated with sulindac or exposed to TBHP). Error bars are standard error of the mean (SEM) expressed as a % of the mean value of four replicate samples from a representative experiment. Significance of the differences between cells treated with and without sulindac, but exposed to the same concentration of TBHP: *p&lt;0.01; ** p&lt;0.001; *** p&lt;0.0001.</p>
            </caption>
            <graphic alt-version="no" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0005804.g001" xlink:type="simple"/>
          </fig>
          <fig id="pone-0005804-g002" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pone.0005804.g002</object-id>
            <label>Figure 2</label>
            <caption>
              <title>Effect of sulindac on the viability of cancer cells in response to hydrogen peroxide.</title>
              <p>Lung cancer cells (A) or colon cancer cells (B) were incubated in the presence (&#9642;) or absence (&#9633;) of 500 &#181;M sulindac for 48 hr. Cells were then washed to remove the free sulindac prior to incubation for 2 hr with the indicated concentration of hydrogen peroxide. Cell viability was measured using the MTS assay described in <xref ref-type="sec" rid="s4">Materials &amp; Methods</xref>. Cell viability is expressed as % of control (cells not pretreated with sulindac or exposed to hydrogen peroxide). Error bars are standard error of the mean (SEM) expressed as a % of the mean value of four replicate samples from a representative experiment. Significance of the differences between cells treated with and without sulindac, but exposed to the same concentration of hydrogen peroxide: *p&lt;0.01; ** p&lt;0.001; *** p&lt;0.0001.</p>
            </caption>
            <graphic alt-version="no" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0005804.g002" xlink:type="simple"/>
          </fig>
          <p>
            <s sid="36">Several lines of evidence indicate that the enhanced killing of cancer cells by sulindac and oxidative stress does not involve COX inhibition.<CoreSc1 atype="GSC" type="Con" conceptID="Con5" novelty="None" advantage="None"/></s>
            <s sid="37">Two other NSAIDs, acetylsalicylic acid (aspirin) and ibuprofen, at 500 &#181;M, failed to increase the sensitivity of cancer cells to oxidative stress (<xref ref-type="fig" rid="pone-0005804-g003">Figure 3A and 3B</xref>, respectively).<CoreSc1 atype="GSC" type="Res" conceptID="Res8" novelty="None" advantage="None"/></s>
            <s sid="38">As noted above, sulindac is a pro-drug that must be converted to the active COX-inhibitor, sulindac sulfide <xref ref-type="bibr" rid="pone.0005804-Duggan1">[19]</xref>, primarily through the activity of MsrA <xref ref-type="bibr" rid="pone.0005804-Etienne1">[20]</xref>.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj5" novelty="None" advantage="None"/></s>
            <s sid="39">To determine whether the enhanced killing of sulindac-treated cancer cells by TBHP involved reduction of sulindac to sulindac sulfide, the active inhibitor of cyclooxygenases, the experiments described above were repeated using sulindac sulfone, which is not a substrate for MsrA (unpublished data) or a COX inhibitor <xref ref-type="bibr" rid="pone.0005804-Babbar1">[28]</xref>.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa2" novelty="None" advantage="None"/></s>
            <s sid="40">Because of increased toxicity of sulindac sulfone a lower concentration (250 &#181;M) was used for these experiments.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp4" novelty="None" advantage="None"/></s>
            <s sid="41">Pretreatment of lung cancer cells with 250 &#181;M sulindac sulfone (<xref ref-type="fig" rid="pone-0005804-g003">Figure 3C</xref>), followed by exposure to TBHP gave comparable results to those seen using 500 &#181;M sulindac (compare <xref ref-type="fig" rid="pone-0005804-g001">Figures 1A</xref> and <xref ref-type="fig" rid="pone-0005804-g003">3C</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res9" novelty="None" advantage="None"/></s>
            <s sid="42">Similar results using sulindac sulfone were also obtained with the colon cancer cells lines (data not shown).<CoreSc1 atype="GSC" type="Res" conceptID="Res10" novelty="None" advantage="None"/></s>
            <s sid="43">Thus, the collective data indicate that the increased sensitivity of sulindac treated cancer cells to oxidative stress, under the conditions used, does not involve either the Msr system or COX inhibition.<CoreSc1 atype="GSC" type="Con" conceptID="Con6" novelty="None" advantage="None"/></s>
          </p>
          <fig id="pone-0005804-g003" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pone.0005804.g003</object-id>
            <label>Figure 3</label>
            <caption>
              <title>Effect of other NSAIDs or sulindac sulfone on the viability of lung cancer cells in response to oxidative stress.</title>
              <p>Lung cancer cells were incubated in the presence (&#9642;) or absence (&#9633;) of either 500 &#181;M acetylsalicylic acid (A), 500 &#181;M ibuprofen (B) or 250 &#181;M sulindac sulfone (C) for 48 hr. Cells were then washed to remove the free NSAID or sulindac sulfone prior to incubation for 2 hr with the indicated concentration of TBHP. Cell viability was measured using the MTS assay described in <xref ref-type="sec" rid="s4">Materials &amp; Methods</xref>. Cell viability is expressed as % of control (cells not exposed to an NSAID, sulindac sulfone, or TBHP). Error bars are standard error of the mean (SEM) expressed as a % of the mean value of four replicate samples from a representative experiment. Significance of the differences between cells treated with and without sulindac sulfone, but exposed to the same concentration of TBHP: *p&lt;0.01; ** p&lt;0.001; *** p&lt;0.0001.</p>
            </caption>
            <graphic alt-version="no" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0005804.g003" xlink:type="simple"/>
          </fig>
        </sec>
        <sec id="s2b">
          <title>Sulindac does not enhance the killing of normal cells exposed to oxidative stress</title>
          <p>
            <s sid="44">It was important to determine whether the enhanced killing effect of sulindac and sulindac sulfone on cancer cells in the presence of TBHP (<xref ref-type="fig" rid="pone-0005804-g001">Figure 1</xref>) also occurred with normal, non-immortalized cells.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot2" novelty="None" advantage="None"/></s>
            <s sid="45"><xref ref-type="fig" rid="pone-0005804-g004">Figure 4</xref> shows the effect of pretreating normal lung cells with sulindac or sulindac sulfone on cell viability after oxidative stress using TBHP.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs3" novelty="None" advantage="None"/></s>
            <s sid="46">Incubation of normal lung cells with 500 &#181;M sulindac for 48 hr prior to exposure to TBHP not only did not enhance killing, but sulindac provided protection from oxidative stress caused by TBHP (<xref ref-type="fig" rid="pone-0005804-g004">Figure 4A</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res11" novelty="None" advantage="None"/></s>
            <s sid="47">The protective effect from oxidative stress on normal lung cells was also observed when cells were pretreated with sulindac sulfone (<xref ref-type="fig" rid="pone-0005804-g004">Figure 4B</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs4" novelty="None" advantage="None"/></s>
          </p>
          <fig id="pone-0005804-g004" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pone.0005804.g004</object-id>
            <label>Figure 4</label>
            <caption>
              <title>Sulindac and sulindac sulfone protect normal lung cells against oxidative stress.</title>
              <p>Normal lung cells were incubated for 48 hr in (A) the presence (&#9642;) or absence (&#9633;) of 500 &#181;M sulindac or (B) the presence (&#9642;) or absence (&#9633;) of 250 &#181;M sulindac. See <xref ref-type="sec" rid="s4">Materials and Methods</xref> and legend to <xref ref-type="fig" rid="pone-0005804-g001">Figure 1</xref> for further details. Significance of the differences between cells treated with and without sulindac or sulindac sulfone, but exposed to the same concentration of TBHP: *p&lt;0.01; ** p&lt;0.001; *** p&lt;0.0001.</p>
            </caption>
            <graphic alt-version="no" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0005804.g004" xlink:type="simple"/>
          </fig>
          <p>
            <s sid="48">Similar experiments were performed using the normal colon cells.<CoreSc1 atype="GSC" type="Met" conceptID="Met1" novelty="None" advantage="None"/></s>
            <s sid="49">There was no effect on cell viability in the presence of TBHP when the normal colon cells were pretreated with either 500 &#181;M sulindac or 250 &#181;M sulindac sulfone (data not shown).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs5" novelty="None" advantage="None"/></s>
            <s sid="50">Thus, neither normal lung nor normal colon cells showed enhanced killing by TBHP following treatment with sulindac or sulindac sulfone, as was observed with the two cancer cell lines.<CoreSc1 atype="GSC" type="Res" conceptID="Res12" novelty="None" advantage="None"/></s>
          </p>
        </sec>
        <sec id="s2c">
          <title>Sulindac pretreatment of lung cancer cells leads to elevated levels of ROS and loss of mitochondrial membrane potential</title>
          <p>
            <s sid="51">Lung cancer cells were used to gain more information on the mechanism of the enhanced killing effect of sulindac in the presence of TBHP.<CoreSc1 atype="GSC" type="Met" conceptID="Met2" novelty="None" advantage="None"/></s>
            <s sid="52">To investigate whether the enhanced killing of the cancer cells observed with sulindac and oxidative stress might involve mitochondrial dysfunction, changes in the level of intracellular ROS were determined.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa3" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met3" novelty="None" advantage="None"/></s>
            <s sid="53">For these experiments lung cancer cells were treated with sulindac for 48 hours, exposed to TBHP and then the intracellular ROS level was visualized using a fluorescent dye as described in the <xref ref-type="sec" rid="s4">Materials and Methods</xref>.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp5" novelty="None" advantage="None"/></s>
            <s sid="54">The results are shown in <xref ref-type="fig" rid="pone-0005804-g005">Figure 5</xref>.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs6" novelty="None" advantage="None"/></s>
            <s sid="55">Compared to untreated lung cancer cells (<xref ref-type="fig" rid="pone-0005804-g005">Figure 5A</xref>), cells treated with sulindac alone (<xref ref-type="fig" rid="pone-0005804-g005">Figure 5B</xref>) or TBHP alone (<xref ref-type="fig" rid="pone-0005804-g005">Figure 5C</xref>) showed a modest increase (53&#8211;58%) in ROS levels based on appearance of green fluorescence.<CoreSc1 atype="GSC" type="Res" conceptID="Res13" novelty="None" advantage="None"/></s>
            <s sid="56">However, lung cancer cells that were pretreated with 500 &#181;M sulindac followed by a 2 hr incubation with 80 &#181;M TBHP (<xref ref-type="fig" rid="pone-0005804-g005">Figure 5D</xref>) had a 400% increase in intracellular green fluorescence compared to untreated cells (compare <xref ref-type="fig" rid="pone-0005804-g005">Figure 5A and 5D</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res14" novelty="None" advantage="None"/></s>
            <s sid="57">These data clearly show that pretreatment of the lung cancer cells with sulindac leads to a large increase in intracellular ROS following exposure to oxidative stress, supporting the results on skin cancer cells reported recently <xref ref-type="bibr" rid="pone.0005804-Resnick1">[27]</xref>.<CoreSc1 atype="GSC" type="Res" conceptID="Res15" novelty="None" advantage="None"/></s>
          </p>
          <fig id="pone-0005804-g005" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pone.0005804.g005</object-id>
            <label>Figure 5</label>
            <caption>
              <title>Intracellular ROS levels in lung cancer cells pretreated with sulindac followed by oxidative stress.</title>
              <p>The panels show intracellular ROS fluorescence. (A) untreated cells; (B) cells treated with only sulindac; (C) cells treated with only TBHP; (D) cells treated with both sulindac and TBHP. The incubation conditions are described in <xref ref-type="fig" rid="pone-0005804-g001">Figure 1</xref>. The cells were prepared for fluorescence microscopy and the green fluorescence signal was quantified as described in <xref ref-type="sec" rid="s4">Materials and Methods</xref>. Fluorescence levels are the average of two independent experiments and were adjusted for the percentage of viable cells. The SEM was less than 10% for each sample. The increase in fluorescence compared to control cells in panel A are: B, 53%; C, 57%; D, 401%.</p>
            </caption>
            <graphic alt-version="no" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0005804.g005" xlink:type="simple"/>
          </fig>
          <p>
            <s sid="58">To further explore the mechanism of killing cancer cells exposed to oxidative stress after pretreatment with sulindac, we investigated whether there is a concomitant loss of mitochondrial membrane potential, which is known to initiate apoptotic cell death.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp2" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Goa" conceptID="Goa4" novelty="None" advantage="None"/></s>
            <s sid="59">Effects on mitochondrial membrane potential were evaluated using changes in the fluorescence of the JC-1 dye as described in <xref ref-type="sec" rid="s4">Materials and Methods</xref>.<CoreSc1 atype="GSC" type="Met" conceptID="Met4" novelty="None" advantage="None"/></s>
            <s sid="60">The results are shown in <xref ref-type="fig" rid="pone-0005804-g006">Figure 6</xref>.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs7" novelty="None" advantage="None"/></s>
            <s sid="61">The top panels show red fluorescent images and the lower panels green fluorescent images.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs8" novelty="None" advantage="None"/></s>
            <s sid="62">Loss of mitochondrial membrane potential would result in decreased red fluorescence and a corresponding increase in green fluorescence.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp6" novelty="None" advantage="None"/></s>
            <s sid="63">Relative to untreated cells (<xref ref-type="fig" rid="pone-0005804-g006">Figure 6A</xref>) or cells treated with only sulindac (<xref ref-type="fig" rid="pone-0005804-g006">Figure 6B</xref>) or TBHP alone (<xref ref-type="fig" rid="pone-0005804-g006">Figure 6C</xref>), sulindac pretreatment of lung cancer cells followed by oxidative stress (<xref ref-type="fig" rid="pone-0005804-g006">Figure 6D</xref>) resulted in disruption of mitochondrial membrane potential as evidenced by nearly a 20-fold increase in green fluorescence (see legend of <xref ref-type="fig" rid="pone-0005804-g006">Figure 6</xref> for additional details).<CoreSc1 atype="GSC" type="Res" conceptID="Res16" novelty="None" advantage="None"/></s>
            <s sid="64">In summary, pretreatment of the lung cancer cells with sulindac followed by treatment with TBHP leads to a marked increase in intracellular ROS and a significant loss of mitochondrial membrane potential.<CoreSc1 atype="GSC" type="Res" conceptID="Res17" novelty="None" advantage="None"/></s>
            <s sid="65">These results indicated that cell death was occurring via apoptosis, which was confirmed by Tunel analysis (Supplementary <xref ref-type="supplementary-material" rid="pone.0005804.s001">Figure S1</xref>)<CoreSc1 atype="GSC" type="Res" conceptID="Res18" novelty="None" advantage="None"/></s>
          </p>
          <fig id="pone-0005804-g006" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pone.0005804.g006</object-id>
            <label>Figure 6</label>
            <caption>
              <title>Mitochondrial membrane potential as measured by JC-1 distribution in lung cancer cells.</title>
              <p>Upper panels show red fluorescence images while lower panels show green fluorescence images. Loss of mitochondrial membrane potential was detected by a decrease of red fluorescence with a concomitant increase of green florescence. The experimental design is described in the legends of <xref ref-type="fig" rid="pone-0005804-g001">Figure 1</xref>. (A) untreated cells; (B) cells treated with only sulindac; (C) cells treated with only TBHP; (D) cells treated with both sulindac and TBHP. The cells were prepared for fluorescence microscopy and the fluorescence signal was quantified as described in <xref ref-type="sec" rid="s4">Materials and Methods</xref>. Results are an average of three independent experiments. SEM was less than 10% for each sample. Quantitative analysis of green fluorescence is expressed as follows in arbitrary units: panel A &#8211;1.39; panel B &#8211;1.23; panel C &#8211;1.29; panel D &#8211;25.3.</p>
            </caption>
            <graphic alt-version="no" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0005804.g006" xlink:type="simple"/>
          </fig>
        </sec>
      </sec>
      <sec id="s3">
        <title>Discussion</title>
        <p>
          <s sid="66">Sulindac and its metabolites, such as sulindac sulfide and sulindac sulfone, have been shown to have anti-cancer activity <xref ref-type="bibr" rid="pone.0005804-Haanen1">[29]</xref>.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac13" novelty="None" advantage="None"/></s>
          <s sid="67">Consistent with our previous study of skin cancer cells <xref ref-type="bibr" rid="pone.0005804-Resnick1">[27]</xref>, we have shown that the killing of lung and colon tumor cell lines can be enhanced significantly if sulindac is combined with an oxidant, such as TBHP or hydrogen peroxide.<CoreSc1 atype="GSC" type="Res" conceptID="Res19" novelty="None" advantage="None"/></s>
          <s sid="68">We also have shown that sulindac pretreatment can enhance the killing of skin cancer cells caused by arsenic trioxide (data not shown), which kills cancer cells by generating intracellular ROS, as reported elsewhere for lung cancer cells <xref ref-type="bibr" rid="pone.0005804-Jiang1">[30]</xref>.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot3" novelty="None" advantage="None"/></s>
          <s sid="69">It seems reasonable that sulindac may enhance the efficacy of any anticancer drug where the mechanism of action involves oxidative damage.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp3" novelty="None" advantage="None"/></s>
          <s sid="70">The successful application of a multiple drug therapy has been recently reported for a clinical trial involving almost 300 patients at risk for recurrence of colorectal adenomas who were treated with a combination of sulindac and difluoromethylornithine, an inhibitor of polyamine synthesis <xref ref-type="bibr" rid="pone.0005804-Meyskens1">[31]</xref>.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac14" novelty="None" advantage="None"/></s>
        </p>
        <p>
          <s sid="71">It appears likely that the mechanism of the selective killing of cancer cells seen in these studies involves mitochondrial dysfunction, possibly as a result of increased ROS production.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp4" novelty="None" advantage="None"/></s>
          <s sid="72">While treatment of cancer cells with sulindac or TBHP individually leads to a modest increase in the level of ROS (<xref ref-type="fig" rid="pone-0005804-g005">Figure 5B</xref> and <xref ref-type="bibr" rid="pone.0005804-Resnick1">[27]</xref>, <xref ref-type="bibr" rid="pone.0005804-Seo1">[32]</xref>), there is a dramatic increase in the intracellular levels of ROS in cells pretreated with sulindac and then exposed to TBHP (<xref ref-type="fig" rid="pone-0005804-g005">Figure 5D</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res20" novelty="None" advantage="None"/></s>
          <s sid="73">In addition, there is a significant disruption of mitochondrial membrane potential under the same experimental conditions (<xref ref-type="fig" rid="pone-0005804-g006">Figure 6</xref>), suggesting that sulindac causes apoptosis in cancer cells exposed to oxidative stress.<CoreSc1 atype="GSC" type="Con" conceptID="Con7" novelty="None" advantage="None"/></s>
          <s sid="74">The anticancer effect of sulindac alone has been reported to involve apoptotic death <xref ref-type="bibr" rid="pone.0005804-Adachi1">[33]</xref>.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac15" novelty="None" advantage="None"/></s>
          <s sid="75">The results with sulindac sulfone and other NSAIDs indicate that the effect of sulindac in our system does not involve COX inhibition or the Msr system.<CoreSc1 atype="GSC" type="Res" conceptID="Res21" novelty="None" advantage="None"/></s>
        </p>
        <p>
          <s sid="76">The present results indicate a fundamental difference in the way normal and cancer cells respond to oxidative stress.<CoreSc1 atype="GSC" type="Con" conceptID="Con8" novelty="None" advantage="None"/></s>
          <s sid="77">Sulindac and its metabolites can accentuate this difference, which leads to enhanced killing of cancer cells, but not normal cells, by oxidative stress.<CoreSc1 atype="GSC" type="Con" conceptID="Con9" novelty="None" advantage="None"/></s>
          <s sid="78">It is well established that cancer and normal cells differ in their oxidative metabolism and that cancer cells have a higher rate of glycolysis than normal cells, a phenomenon first described by Warburg <xref ref-type="bibr" rid="pone.0005804-Warburg1">[34]</xref>.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac16" novelty="None" advantage="None"/></s>
          <s sid="79">There also is compelling evidence that cancer cells are typically under greater oxidative stress compared to normal cells <xref ref-type="bibr" rid="pone.0005804-Pelicano1">[35]</xref>.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac17" novelty="None" advantage="None"/></s>
          <s sid="80">A difference between normal and cancer cells to oxidative stress that has been reported is the cytotoxicity caused by glucose deprivation.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac18" novelty="None" advantage="None"/></s>
          <s sid="81">Studies by Spitz and coworkers <xref ref-type="bibr" rid="pone.0005804-Ahmad1">[36]</xref> have clearly shown that this effect is mediated by mitochondrial ROS production.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac19" novelty="None" advantage="None"/></s>
        </p>
        <p>
          <s sid="82">The results described provide further evidence that a combination of sulindac and an oxidizing agent might have clinical therapeutic value in treating a variety of cancers.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot4" novelty="None" advantage="None"/></s>
          <s sid="83">In a previous preliminary study we reported that the results of a limited proof of concept human clinical trial using sulindac (1&#8211;5%) and hydrogen peroxide (25%) gels applied daily for three weeks on actinic keratoses (AK) involving the upper extremities <xref ref-type="bibr" rid="pone.0005804-Resnick1">[27]</xref>.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac20" novelty="None" advantage="None"/></s>
          <s sid="84">Upon completion, all ten treated AKs showed a reduction in size as shown by clinical photography with five exhibiting complete disappearance of the precancerous cells after skin biopsy.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac21" novelty="None" advantage="None"/></s>
          <s sid="85">These preliminary results warrant more extensive clinical trials.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot5" novelty="None" advantage="None"/></s>
        </p>
      </sec>
      <sec id="s4">
        <title>Materials and Methods</title>
        <sec id="s4a">
          <title>Materials</title>
          <p>
            <s sid="86">Sulindac, acetylsalicylic acid (aspirin), (S)-(+)-ibuprofen, and tert butyl-hydroperoxide (TBHP) were obtained from Sigma (St. Louis, MO).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp7" novelty="None" advantage="None"/></s>
            <s sid="87">Sulindac sulfone was synthesized by Custom Synthesis Inc. (Boca Raton, FL).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp8" novelty="None" advantage="None"/></s>
            <s sid="88">All tissue culture media including fetal bovine serum and other supplements were purchased from American Type Culture Collection (ATCC; Rockville, MD).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp9" novelty="None" advantage="None"/></s>
          </p>
        </sec>
        <sec id="s4b">
          <title>Cell Culture</title>
          <p>
            <s sid="89">A colon cancer cell line (RKO), a lung cancer cell line (A549), and fibroblast cell lines derived from normal human colon tissue (CCD-18Co) and normal human lung (MRC-5) were obtained from ATCC (Rockville, MD).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp10" novelty="None" advantage="None"/></s>
            <s sid="90">All cell lines were maintained in the recommended culture medium.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp11" novelty="None" advantage="None"/></s>
            <s sid="91">The normal cell lines were not immortalized and early passage cells were used for the experiments reported here.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp12" novelty="None" advantage="None"/></s>
            <s sid="92">Cell lines were determined to be free of mycoplasma using the VenorGeM&#174; Mycoplasma Detection Kit (Sigma-Aldrich), which is a highly sensitive PCR-based assay.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp13" novelty="None" advantage="None"/></s>
          </p>
        </sec>
        <sec id="s4c">
          <title>Cell Viability Assay</title>
          <p>
            <s sid="93">Unless otherwise indicated, the cells were pretreated with sulindac, sulindac sulfone or another NSAID for 48 hr prior to exposure to TBHP for 2 hr.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp14" novelty="None" advantage="None"/></s>
            <s sid="94">Cell suspensions (&#8764;100,000 cells) containing the indicated supplement were plated in 96 well microtiter plates using 100 &#181;l of the indicated cell suspension.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp15" novelty="None" advantage="None"/></s>
            <s sid="95">The plates were incubated for 48 hr at 37&#176;C in a 5% CO<sub>2</sub> incubator.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp16" novelty="None" advantage="None"/></s>
            <s sid="96">The culture medium was then removed and the cells washed once with fresh culture medium with serum.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp17" novelty="None" advantage="None"/></s>
            <s sid="97">After removal of the wash solution, fresh culture medium with serum that contained the indicated final concentration of TBHP or hydrogen peroxide was added to the cells, and the cells were incubated an additional 2 hours.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp18" novelty="None" advantage="None"/></s>
            <s sid="98">Similar results were obtained when sulindac was included during the 2 hr treatment with the oxidizing agent.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs9" novelty="None" advantage="None"/></s>
          </p>
          <p>
            <s sid="99">Cell viability was determined by the CellTiter 96 Aqueous One Cell Proliferation Assay (Promega; Madison, WI) according to the manufacture's instructions.<CoreSc1 atype="GSC" type="Met" conceptID="Met5" novelty="None" advantage="None"/></s>
            <s sid="100">The assay utilizes a novel tetrazolium compound that metabolically active cells convert to a water-soluble formazan by the action of cellular dehydrogenases, which is measured by absorbance at 490 nm using a colorimetric microtiter plate reader (SpectraMax Plus<sup>384</sup>; Molecular Devices).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp19" novelty="None" advantage="None"/></s>
            <s sid="101">Background absorbance was subtracted from each sample.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp20" novelty="None" advantage="None"/></s>
            <s sid="102">It has been reported that some anticancer drugs can cause changes in absorbance in MTS-based assays for cell viability in the absence of cells <xref ref-type="bibr" rid="pone.0005804-Ulukaya1">[37]</xref>.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac22" novelty="None" advantage="None"/></s>
            <s sid="103">Control experiments using sulindac alone, TBHP alone or combinations of sulindac and TBHP over the concentration range used in the reported experiments showed no effect of either compound alone or in combination on absorbance.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs10" novelty="None" advantage="None"/></s>
          </p>
        </sec>
        <sec id="s4d">
          <title>Intracellular ROS Assay</title>
          <p>
            <s sid="104">Intracellular ROS levels were determined by using the Reactive Oxygen Species (ROS) Detection Reagents from Molecular Probes (Eugene, OR) as described elsewhere <xref ref-type="bibr" rid="pone.0005804-Rohnstock1">[38]</xref>.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp21" novelty="None" advantage="None"/></s>
            <s sid="105">Elevated levels of ROS result in increased green fluorescence, which was visualized by fluorescence microscopy.<CoreSc1 atype="GSC" type="Met" conceptID="Met6" novelty="None" advantage="None"/></s>
          </p>
        </sec>
        <sec id="s4e">
          <title>JC-1 assay to measure mitochondrial membrane potential</title>
          <p>
            <s sid="106">Loss of mitochondrial membrane potential was determined using the JC-1 dye from Molecular Probes (Eugene, OR).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp22" novelty="None" advantage="None"/></s>
            <s sid="107">Loss of mitochondrial membrane potential leads to increased green fluorescence in the cytosol and a corresponding decrease in mitochondrial red fluorescence.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj6" novelty="None" advantage="None"/></s>
            <s sid="108">Thus, changes in mitochondrial membrane potential were determined by following the red to green staining shift using an FITC filter (Zeiss inverted microscope-Axiovert 40 CFL).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp23" novelty="None" advantage="None"/></s>
            <s sid="109">Quantitation of the fluorescence signals used both standard densitometric methods and a Photoshop (Adobe Systems, San Jose, CA) based image analysis <xref ref-type="bibr" rid="pone.0005804-Lehr1">[39]</xref>.<CoreSc1 atype="GSC" type="Met" conceptID="Met7" novelty="None" advantage="None"/></s>
          </p>
        </sec>
        <sec id="s4f">
          <title>TUNEL Assay to demonstrate apoptosis</title>
          <p>
            <s sid="110">Apoptotic cells were detected using the Deadend (Promega) colorimetric TUNEL assay that end labels fragmented DNA.<CoreSc1 atype="GSC" type="Met" conceptID="Met8" novelty="None" advantage="None"/></s>
            <s sid="111">Cells were fixed with 4% formaldehyde before being permeabilized with 0.2% triton-X-100.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp24" novelty="None" advantage="None"/></s>
            <s sid="112">Cells were then washed with PBS prior to incubation with recombinant terminal deoxynucleotidyl transferase(TdT) and biotinylated nucleotides for 1 h at 37&#176;C, which incorporates the biotinylated nucleotides at 3&#8242; ends of fragmented DNA.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp25" novelty="None" advantage="None"/></s>
            <s sid="113">Cells were washed with PBS and then incubated with horseradish peroxidase-streptavidin (HRP-Streptavidin) at room temperature for 30 min.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp26" novelty="None" advantage="None"/></s>
            <s sid="114">HRP-streptavidin labeled cells were detected by hydrogen peroxide and diaminobenzidine (DAB).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp27" novelty="None" advantage="None"/></s>
            <s sid="115">Apoptotic cells are visualized by dark brown nuclear staining.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp28" novelty="None" advantage="None"/></s>
          </p>
        </sec>
        <sec id="s4g">
          <title>Statistical analysis</title>
          <p>
            <s sid="116">Results of cell viability experiments are expressed as the mean of four replicates of a representative experiment.<CoreSc1 atype="GSC" type="Met" conceptID="Met9" novelty="None" advantage="None"/></s>
            <s sid="117">The error bars indicate the standard error of the mean (SEM).<CoreSc1 atype="GSC" type="Met" conceptID="Met10" novelty="None" advantage="None"/></s>
            <s sid="118">Means were compared using standard t-tests and the P-values are indicated in the figure legends.<CoreSc1 atype="GSC" type="Met" conceptID="Met11" novelty="None" advantage="None"/></s>
            <s sid="119">P values&lt;0.05 were considered statistically significant.<CoreSc1 atype="GSC" type="Met" conceptID="Met12" novelty="None" advantage="None"/></s>
            <s sid="120">Quantitation of the fluorescence signals used both standard densitometric methods and a Photoshop (Adobe Systems, San Jose, CA) based image analysis <xref ref-type="bibr" rid="pone.0005804-Lehr1">[39]</xref>.<CoreSc1 atype="GSC" type="Met" conceptID="Met13" novelty="None" advantage="None"/></s>
          </p>
        </sec>
      </sec>
      <sec id="s5">
        <title>Supporting Information</title>
        <supplementary-material id="pone.0005804.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0005804.s001" xlink:type="simple">
          <label>Figure S1</label>
          <caption>
            <p>Cell Death due to Apoptosis. A TUNEL assay was used to detect apoptosis of lung cancer cells. (A) untreated cells; (B) cells treated with only 500 &#181;M sulindac; (C) cells treated with only 180 &#181;M TBHP; (D) cells treated with both 500 &#181;M sulindac and 180 &#181;M TBHP. Increased levels of apoptosis are indicated by enhanced formation of brown coloration. The experimental design is described in the legends of <xref ref-type="fig" rid="pone-0005804-g001">Figure 1</xref> in the manuscript. Additional details of the TUNEL assay are provided in the <xref ref-type="sec" rid="s4">Materials and Methods</xref>.</p>
            <p>(0.22 MB TIF)</p>
          </caption>
        </supplementary-material>
      </sec>
    </body>
    <back>
      <ack>
        <p>We would like to acknowledge Dr. Daphna Sagher for her assistance and helpful discussions. We would also like to thank Kelsey Binninger for her help with the artwork.</p>
      </ack>
      <ref-list>
        <title>References</title>
        <ref id="pone.0005804-Vane1">
          <label>1</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Vane</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <year>1971</year>
            <article-title>Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.</article-title>
            <source>Nat New Biol</source>
            <volume>231</volume>
            <fpage>232</fpage>
            <lpage>235</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Boolbol1">
          <label>2</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Boolbol</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Dannenberg</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Chadburn</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Martucci</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Lipkin</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <year>1996</year>
            <article-title>Cyclooxygenase-2 over-expression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.</article-title>
            <source>Cancer Res</source>
            <volume>56</volume>
            <fpage>2556</fpage>
            <lpage>2560</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Gwyn1">
          <label>3</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gwyn</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Sinicrope</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <year>2002</year>
            <article-title>Chemoprevention of colorectal cancer.</article-title>
            <source>Am J Gastroenterol</source>
            <volume>97</volume>
            <fpage>13</fpage>
            <lpage>21</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Taketo1">
          <label>4</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Taketo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <year>1998</year>
            <article-title>Cyclooxygenase-2 inhibitors in tumoregenesis (part 2).</article-title>
            <source>J Natl Cancer Inst</source>
            <volume>90</volume>
            <fpage>1609</fpage>
            <lpage>1620</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Taketo2">
          <label>5</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Taketo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <year>1998</year>
            <article-title>Cyclooxygenase-2 inhibitors in tumorigenesis (part 1).</article-title>
            <source>J Natl Cancer Inst</source>
            <volume>90</volume>
            <fpage>1529</fpage>
            <lpage>1536</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Guldenschuh1">
          <label>6</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Guldenschuh</surname>
                <given-names>I</given-names>
              </name>
              <name name-style="western">
                <surname>Hurlimann</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Muller</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Ammann</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Mullhaupt</surname>
                <given-names>B</given-names>
              </name>
              <etal/>
            </person-group>
            <year>2001</year>
            <article-title>Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis.</article-title>
            <source>Dis Colon Rectum</source>
            <volume>44</volume>
            <fpage>1090</fpage>
            <lpage>1097</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Rao1">
          <label>7</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Rao</surname>
                <given-names>KV</given-names>
              </name>
              <name name-style="western">
                <surname>Detrisac</surname>
                <given-names>CJ</given-names>
              </name>
              <name name-style="western">
                <surname>Steele</surname>
                <given-names>VE</given-names>
              </name>
              <name name-style="western">
                <surname>Hawk</surname>
                <given-names>ET</given-names>
              </name>
              <name name-style="western">
                <surname>Kelloff</surname>
                <given-names>GJ</given-names>
              </name>
              <etal/>
            </person-group>
            <year>1996</year>
            <article-title>Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder.</article-title>
            <source>Carcinogenesis</source>
            <volume>17</volume>
            <fpage>1435</fpage>
            <lpage>1438</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Grosch1">
          <label>8</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Grosch</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Tegeder</surname>
                <given-names>I</given-names>
              </name>
              <name name-style="western">
                <surname>Niederberger</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Brautigam</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Geisslinger</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <year>2001</year>
            <article-title>Cox-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective cox-2 inhibitor celecoxib.</article-title>
            <source>FASEB J</source>
            <volume>15</volume>
            <fpage>2742</fpage>
            <lpage>2744</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Tegeder1">
          <label>9</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Tegeder</surname>
                <given-names>I</given-names>
              </name>
              <name name-style="western">
                <surname>Pfeilschifter</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Geisslinger</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <year>2001</year>
            <article-title>Cyclooxygenase-independent actions of cyclooxygenase inhibitors.</article-title>
            <source>FASEB J</source>
            <volume>15</volume>
            <fpage>2057</fpage>
            <lpage>2072</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Vogt1">
          <label>10</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Vogt</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>McClelland</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Jung</surname>
                <given-names>B</given-names>
              </name>
              <name name-style="western">
                <surname>Popova</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Bogenrieder</surname>
                <given-names>T</given-names>
              </name>
              <etal/>
            </person-group>
            <year>2001</year>
            <article-title>Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II.</article-title>
            <source>Melanoma Res</source>
            <volume>11</volume>
            <fpage>587</fpage>
            <lpage>599</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Yamazaki1">
          <label>11</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Yamazaki</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Kusunoki</surname>
                <given-names>N</given-names>
              </name>
              <name name-style="western">
                <surname>Matsuzaki</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Hashimoto</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Kawai</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <year>2002</year>
            <article-title>Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells.</article-title>
            <source>FEBS Lett</source>
            <volume>531</volume>
            <fpage>278</fpage>
            <lpage>284</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Richter1">
          <label>12</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Richter</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Weiss</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Weinberger</surname>
                <given-names>I</given-names>
              </name>
              <name name-style="western">
                <surname>Furstenberger</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Marian</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <year>2001</year>
            <article-title>Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors.</article-title>
            <source>Carcinogenesis</source>
            <volume>22</volume>
            <fpage>17</fpage>
            <lpage>25</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Bauvy1">
          <label>13</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bauvy</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Gane</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>Arico</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Codogno</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>Ogier-Denis</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <year>2001</year>
            <article-title>Autophagy delays sulindac sulfide-induced apoptosis in the human intestinal colon cancer cell line HT-29.</article-title>
            <source>Exp Cell Res</source>
            <volume>268</volume>
            <fpage>139</fpage>
            <lpage>149</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Bonnesen1">
          <label>14</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bonnesen</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Eggleston</surname>
                <given-names>I</given-names>
              </name>
              <name name-style="western">
                <surname>Hayes</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <year>2001</year>
            <article-title>Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in colon cell lines.</article-title>
            <source>Cancer Res</source>
            <volume>61</volume>
            <fpage>6120</fpage>
            <lpage>6130</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Bottone1">
          <label>15</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bottone</surname>
                <given-names>F</given-names>
                <suffix>Jr</suffix>
              </name>
              <name name-style="western">
                <surname>Martinez</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Collins</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Afshari</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Eling</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <year>2003</year>
            <article-title>Gene modulation by cyclooxygenase inhibitor, sulindac sulfide, in human colorectal carcinoma cells.</article-title>
            <source>Biol Chem</source>
            <volume>278</volume>
            <fpage>25790</fpage>
            <lpage>25801</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Huang1">
          <label>16</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>He</surname>
                <given-names>Q</given-names>
              </name>
              <name name-style="western">
                <surname>Hillman</surname>
                <given-names>MJ</given-names>
              </name>
              <name name-style="western">
                <surname>Rong</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Sheikh</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <year>2001</year>
            <article-title>Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells.</article-title>
            <source>Cancer Res</source>
            <volume>61</volume>
            <fpage>6918</fpage>
            <lpage>6924</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Ravi1">
          <label>17</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ravi</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Bedi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <year>2002</year>
            <article-title>Requirement for BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers.</article-title>
            <source>Cancer Res</source>
            <volume>62</volume>
            <fpage>1583</fpage>
            <lpage>1587</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Wick1">
          <label>18</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wick</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Hurteau</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Dessey</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Chan</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Geraci</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <year>2002</year>
            <article-title>Peroxisome proliferator-activated receptor-g is a target of non-steroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth.</article-title>
            <source>Mol Pharmacol</source>
            <volume>62</volume>
            <fpage>1207</fpage>
            <lpage>1214</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Duggan1">
          <label>19</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Duggan</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Hooke</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Risley</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Shen</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Van Arman</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <year>1977</year>
            <article-title>Identification of the biologically active form of sulindac.</article-title>
            <source>J Pharmacol Expr Therapeut</source>
            <volume>201</volume>
            <fpage>8</fpage>
            <lpage>13</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Etienne1">
          <label>20</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Etienne</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Resnick</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Sagher</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Brot</surname>
                <given-names>N</given-names>
              </name>
              <name name-style="western">
                <surname>Weissbach</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <year>2003</year>
            <article-title>Reduction of Sulindac to its active metabolite, sulindac sulfide: assay and role of the methionine sulfoxide reductase system.</article-title>
            <source>Biochem Biophys Res Commun</source>
            <volume>312</volume>
            <fpage>1005</fpage>
            <lpage>1010</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Moskovitz1">
          <label>21</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Moskovitz</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <year>2005</year>
            <article-title>Methionine sulfoxide reductases: ubiquitous enzymes involved in antioxidant defense, protein regulation, and prevention of aging-associated diseases.</article-title>
            <source>Biochim Biophys Acta</source>
            <volume>1703</volume>
            <fpage>213</fpage>
            <lpage>219</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Ruan1">
          <label>22</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ruan</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Tang</surname>
                <given-names>XD</given-names>
              </name>
              <name name-style="western">
                <surname>Chen</surname>
                <given-names>M-L</given-names>
              </name>
              <name name-style="western">
                <surname>Joiner</surname>
                <given-names>MA</given-names>
              </name>
              <name name-style="western">
                <surname>Sun</surname>
                <given-names>G</given-names>
              </name>
              <etal/>
            </person-group>
            <year>2002</year>
            <article-title>High-quality life extension by the enzyme peptide methionine sulfoxide reductase.</article-title>
            <source>Proc Natl Acad Sci, USA</source>
            <volume>99(5)</volume>
            <fpage>2748</fpage>
            <lpage>2753</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Weissbach1">
          <label>23</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Weissbach</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Resnick</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Brot</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <year>2005</year>
            <article-title>Methionine sulfoxide reductases: history and cellular role in protecting against oxidative damage.</article-title>
            <source>Biochim Biophys Acta</source>
            <volume>1703</volume>
            <fpage>203</fpage>
            <lpage>212</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Levine1">
          <label>24</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Levine</surname>
                <given-names>RL</given-names>
              </name>
              <name name-style="western">
                <surname>M</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Berlett</surname>
                <given-names>BS</given-names>
              </name>
              <name name-style="western">
                <surname>Stadtman</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <year>1996</year>
            <article-title>Methionine residues as endogenous antioxidants in protein.</article-title>
            <source>Proc natl Acad Sci USA</source>
            <volume>93</volume>
            <fpage>15036</fpage>
            <lpage>15040</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Yermolaieva1">
          <label>25</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Yermolaieva</surname>
                <given-names>O</given-names>
              </name>
              <name name-style="western">
                <surname>Xu</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Schinstock</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Brot</surname>
                <given-names>N</given-names>
              </name>
              <name name-style="western">
                <surname>Weissbach</surname>
                <given-names>H</given-names>
              </name>
              <etal/>
            </person-group>
            <year>2004</year>
            <article-title>Methionine sulfoxide reductase A protects neuronal cells against brief hypoxia/reoxygenation.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <volume>101</volume>
            <fpage>1159</fpage>
            <lpage>1164</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Marchetti1">
          <label>26</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Marchetti</surname>
                <given-names>MA</given-names>
              </name>
              <name name-style="western">
                <surname>Pizarro</surname>
                <given-names>GO</given-names>
              </name>
              <name name-style="western">
                <surname>Sagher</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Deamicis</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Brot</surname>
                <given-names>N</given-names>
              </name>
              <etal/>
            </person-group>
            <year>2005</year>
            <article-title>Methionine sulfoxide reductases B1, B2, and B3 are present in the human lens and confer oxidative stress resistance to lens cells.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <volume>46</volume>
            <fpage>2107</fpage>
            <lpage>2112</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Resnick1">
          <label>27</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Resnick</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Rabinovitz</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Binninger</surname>
                <given-names>DM</given-names>
              </name>
              <name name-style="western">
                <surname>Marchetti</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Weissbach</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <year>2009</year>
            <article-title>Topical sulindac combined with hydrogen peroxide in the treatment of actinic kratoses: Rationale and clinical trial.</article-title>
            <source>J Drugs in Dermatology</source>
            <volume>8</volume>
            <fpage>1241</fpage>
            <lpage>1244</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Babbar1">
          <label>28</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Babbar</surname>
                <given-names>N</given-names>
              </name>
              <name name-style="western">
                <surname>Ignatenko</surname>
                <given-names>NA</given-names>
              </name>
              <name name-style="western">
                <surname>Casero</surname>
                <given-names>RA</given-names>
                <suffix>Jr</suffix>
              </name>
              <name name-style="western">
                <surname>Gerner</surname>
                <given-names>EW</given-names>
              </name>
            </person-group>
            <year>2003</year>
            <article-title>Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer.</article-title>
            <source>J Biol Chem</source>
            <volume>278</volume>
            <fpage>47762</fpage>
            <lpage>47775</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Haanen1">
          <label>29</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Haanen</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <year>2001</year>
            <article-title>Sulindac and its derivatives: a novel class of anticancer agents.</article-title>
            <source>Curr Opin Investig Drugs</source>
            <volume>2</volume>
            <fpage>677</fpage>
            <lpage>683</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Jiang1">
          <label>30</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Jiang</surname>
                <given-names>TT</given-names>
              </name>
              <name name-style="western">
                <surname>Brown</surname>
                <given-names>SL</given-names>
              </name>
              <name name-style="western">
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <year>2004</year>
            <article-title>Combined effect of arsenic trioxide and sulindac sulfide in A549 human lung cancer cells in vitro.</article-title>
            <source>J Exp Clin Cancer Res</source>
            <volume>23</volume>
            <fpage>259</fpage>
            <lpage>262</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Meyskens1">
          <label>31</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Meyskens</surname>
                <given-names>FL</given-names>
              </name>
              <name name-style="western">
                <surname>McLaren</surname>
                <given-names>CE</given-names>
              </name>
              <name name-style="western">
                <surname>Pelot</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Fujikawa-Brooks</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Carpentar</surname>
                <given-names>PM</given-names>
              </name>
              <etal/>
            </person-group>
            <year>2008</year>
            <article-title>Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled double-blind trial.</article-title>
            <source>Cancer Prevention Research</source>
            <volume>1</volume>
            <comment>In Press</comment>
          </citation>
        </ref>
        <ref id="pone.0005804-Seo1">
          <label>32</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Seo</surname>
                <given-names>SK</given-names>
              </name>
              <name name-style="western">
                <surname>Lee</surname>
                <given-names>HC</given-names>
              </name>
              <name name-style="western">
                <surname>Woo</surname>
                <given-names>SH</given-names>
              </name>
              <name name-style="western">
                <surname>Jin</surname>
                <given-names>HO</given-names>
              </name>
              <name name-style="western">
                <surname>Yoo</surname>
                <given-names>DH</given-names>
              </name>
              <etal/>
            </person-group>
            <year>2007</year>
            <article-title>Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction.</article-title>
            <source>Apoptosis</source>
            <volume>12</volume>
            <fpage>195</fpage>
            <lpage>209</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Adachi1">
          <label>33</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Adachi</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Sakamoto</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Kawamura</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name name-style="western">
                <surname>Imai</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <year>2007</year>
            <article-title>Nonsteroidal anti-inflammatory drugs and oxidative stress in cancer cells.</article-title>
            <source>Histol Histopathol</source>
            <volume>22</volume>
            <fpage>437</fpage>
            <lpage>442</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Warburg1">
          <label>34</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Warburg</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <year>1956</year>
            <article-title>On the origin of cancer cells.</article-title>
            <source>Science</source>
            <volume>123</volume>
            <fpage>309</fpage>
            <lpage>314</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Pelicano1">
          <label>35</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Pelicano</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Carney</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Huang</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <year>2004</year>
            <article-title>ROS stress in cancer cells and therapeutic implications.</article-title>
            <source>Drug Resist Updat</source>
            <volume>7</volume>
            <fpage>97</fpage>
            <lpage>110</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Ahmad1">
          <label>36</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ahmad</surname>
                <given-names>IM</given-names>
              </name>
              <name name-style="western">
                <surname>Aykin-Burns</surname>
                <given-names>N</given-names>
              </name>
              <name name-style="western">
                <surname>Sim</surname>
                <given-names>JE</given-names>
              </name>
              <name name-style="western">
                <surname>Walsh</surname>
                <given-names>SA</given-names>
              </name>
              <name name-style="western">
                <surname>Higashikubo</surname>
                <given-names>R</given-names>
              </name>
              <etal/>
            </person-group>
            <year>2005</year>
            <article-title>Mitochondrial O2*- and H2O2 mediate glucose deprivation-induced stress in human cancer cells.</article-title>
            <source>J Biol Chem</source>
            <volume>280</volume>
            <fpage>4254</fpage>
            <lpage>4263</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Ulukaya1">
          <label>37</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ulukaya</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Colakogullari</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Wood</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <year>2004</year>
            <article-title>Interference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assay.</article-title>
            <source>Chemotherapy</source>
            <volume>50</volume>
            <fpage>43</fpage>
            <lpage>50</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Rohnstock1">
          <label>38</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Rohnstock</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Lehmann</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <year>2007</year>
            <article-title>Evaluation of the probe dihydrocalcein acetoxymethylester as an indicator of reactive oxygen species formation and comparison with oxidative DNA base modification determined by modified alkaline elution technique.</article-title>
            <source>Toxicol In Vitro</source>
            <volume>21</volume>
            <fpage>1552</fpage>
            <lpage>1562</lpage>
          </citation>
        </ref>
        <ref id="pone.0005804-Lehr1">
          <label>39</label>
          <citation citation-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lehr</surname>
                <given-names>HA</given-names>
              </name>
              <name name-style="western">
                <surname>Mankoff</surname>
                <given-names>DA</given-names>
              </name>
              <name name-style="western">
                <surname>Corwin</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Santeusanio</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Gown</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <year>1997</year>
            <article-title>Application of Photoshop-based image analysis to quantification of hormone receptor expression in breast cancer.</article-title>
            <source>J Histochem Cytochem</source>
            <volume>45</volume>
            <fpage>1559</fpage>
            <lpage>1565</lpage>
          </citation>
        </ref>
      </ref-list>
      <fn-group>
        <fn fn-type="conflict">
          <p>The authors have declared that no competing interests exist.</p>
        </fn>
        <fn fn-type="financial-disclosure">
          <p>This work was supported in part by a Center of Excellence in Biomedical and Marine Biotechnology grant from the State of Florida (grant 1140-190-43 awarded to DB and HW). Additional support provided by the National Institutes of Health (1 R15 CA 122001-01A1 awarded to HW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
        </fn>
      </fn-group>
    </back>
  </article>
</PAPER>